Answers are grounded in this paper and cite their sources.
Danazol has recently been reported to be an effective mode of treatment for patients with refractory immune thrombocytopenic purpura. Following a 3 month trial of danazol, only one of 10 patients experienced a sustained increase in platelet counts and two other patients had a transient improvement. While the drug was well tolerated, it does not appear to be particularly helpful in the management of these patients.
No takes yet. Share an insight, caveat, or question.
McVerry et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: